Taraswi Mitra Ghosh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Taraswi Mitra Ghosh has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Amit Kumar Mitra
Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL
81 shared publications - Ahmed Alnaim
Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia
80 shared publications - Allison E. Church Bird
Flow Cytometry and High-Speed Cell Sorting Laboratory, Auburn University, Auburn, Alabama
80 shared publications - Amarjit Mishra
Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, Alabama
80 shared publications - Ayuba Akinpelu
Department of Chemical Engineering, Auburn University, Auburn, AL 36849, USA
80 shared publications - Clayton C. Yates
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland
80 shared publications
Latest Publications
- Open Access
Clofazimine treatment modulates key non-coding RNAs associated with tumor progression and drug resistance in lethal Prostate Cancer
Prostate cancer (PCa) is the most commonly diagnosed cancer and the second-leading cause of cancer death among men in the United States, representing 24.3% of all new cancer cases in the US. Metastatic castration-resistant prostate cancer (mCRPC) is a clinically advanced form of PCa that is associated with increased aggressiveness, cancer stemness, morbidity, and the risk of developing resistance to taxanes, currently the first-line chemotherapeutic agents for mCRPC.Development of new target-directed drugs to treat mCRPC poses significant challenges, given the recognition that monospecific inhibitors have limited efficacy. Hence, there is an urgent medical need to develop new strategies that block major oncogenic signaling pathways driving the most lethal forms of PCa. Clofazimine (CLF) is a potential immunomodulator drug that is FDA-approved for the treatment of leprosy. Recently, using a phenotype-based high-throughput drug screening, we demonstrated the in vitro (cell lines), in vivo (mouse xenograft models), and ex vivo (patient-derived primary tumor cells) efficacy of CLF in drug-resistant forms of chronic myeloid leukemia and multiple myeloma. In this study, we demonstrate that CLF is effective as a single agent and in combination with docetaxel (DTX) in a panel of PCa cell lines representing the diversity of CRPC patients. We also found that CLF reduces aldehyde dehydrogenase activity, which is a marker for cancer ‘stem-like’ cells (CSCs), a subtype of cancer cells with self-renewal and differentiation capacities (acquisition of mesenchymal phenotype or epithelial to mesenchymal transdifferentiation/EMT) that significantly contribute to tumor aggressiveness and the development of drug resistance. Further, using a microfluidic assay, we showed the impact of CLF on cancer cell migration and metastatic potential. Drug-induced changes were investigated using bulk tumor and single-cell RNA sequencing followed by functional analysis of top gene/pathway signatures, where CLF treatment was found to modulate cellular pathways associated with apoptosis, ER stress, oxidative phosphorylation, and mitochondrial dysfunction. Most importantly, CLF modulates the expression of several non-coding RNAs, including MALAT1 and NEAT1, that are linked to tumor cell proliferation, cell migration, and drug resistance. In silico validation of the non-coding RNA signature was performed using multiple patient datasets. Our results support the preclinical development of CLF against lethal PCa and provide novel insights into its mechanism of action.
Open AccessClofazimine treatment modulates key non-coding RNAs associated with tumor progression and drug resistance in lethal Prostate Cancer
Prostate cancer (PCa) is the most commonly diagnosed cancer and the second-leading cause of cancer death among men in the United States, representing 24.3% of all new cancer cases in the US. Metastatic castration-resistant prostate cancer (mCRPC) is a clinically advanced form of PCa that is associated with increased aggressiveness, cancer stemness, morbidity, and the risk of developing resistance to taxanes, currently the first-line chemotherapeutic agents for mCRPC.Development of new target-directed drugs to treat mCRPC poses significant challenges, given the recognition that monospecific inhibitors have limited efficacy. Hence, there is an urgent medical need to develop new strategies that block major oncogenic signaling pathways driving the most lethal forms of PCa. Clofazimine (CLF) is a potential immunomodulator drug that is FDA-approved for the treatment of leprosy. Recently, using a phenotype-based high-throughput drug screening, we demonstrated the in vitro (cell lines), in vivo (mouse xenograft models), and ex vivo (patient-derived primary tumor cells) efficacy of CLF in drug-resistant forms of chronic myeloid leukemia and multiple myeloma. In this study, we demonstrate that CLF is effective as a single agent and in combination with docetaxel (DTX) in a panel of PCa cell lines representing the diversity of CRPC patients. We also found that CLF reduces aldehyde dehydrogenase activity, which is a marker for cancer ‘stem-like’ cells (CSCs), a subtype of cancer cells with self-renewal and differentiation capacities (acquisition of mesenchymal phenotype or epithelial to mesenchymal transdifferentiation/EMT) that significantly contribute to tumor aggressiveness and the development of drug resistance. Further, using a microfluidic assay, we showed the impact of CLF on cancer cell migration and metastatic potential. Drug-induced changes were investigated using bulk tumor and single-cell RNA sequencing followed by functional analysis of top gene/pathway signatures, where CLF treatment was found to modulate cellular pathways associated with apoptosis, ER stress, oxidative phosphorylation, and mitochondrial dysfunction. Most importantly, CLF modulates the expression of several non-coding RNAs, including MALAT1 and NEAT1, that are linked to tumor cell proliferation, cell migration, and drug resistance. In silico validation of the non-coding RNA signature was performed using multiple patient datasets. Our results support the preclinical development of CLF against lethal PCa and provide novel insights into its mechanism of action.
- Open Access
- 19 July 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 6 from Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers
Metronomic topotecan treatment as a single agent and in combination with DTX reduces EMT/stemness in ARLow/mCRPC/NEPC clonally derived taxane-resistant prostate cancer subtypes. A, Assessment of posttreated “stem-like” cells (CD44high/CD133high) population in taxane-resistant ARLow/mCRPC cell lines by Flow cytometry: DUTXR cells line stained with stemness markers (CD44, CD33, and both CD44/133) after CONV-TOPO, METRO-TOPO, and combination (CONV-DTX+METRO-TOPO) treatments. CONV-TOPO, METRO-TOPO, and combination (CONV-DTX+METRO-TOPO) treatments reduced CD44high cells 81.0%, 71.5%, and 63.4%, respectively, in taxane-resistant ARLow mCRPC DUTXR cells. Therefore, METRO-TOPO as single agent and in combination treatment reduced the highest percentage of “stem like” cell population load (P < 0.05; Table 2). B, Colony-forming assay: Number and size of colonies were reduced after all treatments compared with control (no-drug treatment). Next, combination treatment with CONV-DTX+METRO-TOPO reduced the number and size of colonies the greatest compared with CONV-TOPO, CONV-DTX, and METRO-TOPO treatments in the DUTXR cell line. Posttreatment colony number and size reduction in the following order: CONV-TOPO>CONV-DTX>METRO-TOPO>Combination (METRO-TOPO+CONV-DTX). Therefore, METRO-TOPO as a single agent or in combination reduced highest number of the colony and size compared with other treatments. Colonies were developed for 21 days (*, P ≤ 0.05). C, Immunoblot analysis: Proteins representing top EMT markers were downregulated significantly after METRO-TOPO treatment compared with CONV-TOPO treatment in ARLow/mCSPC/NEPCtaxane-resistant (DUTXR) prostate cancer cell lines. Combination treatment (CONV-DTX+METRO-TOPO) exhibited the highest downregulation of EMT marker proteins compared with other treatments. Posttreatment protein expression downregulation was following orders: CONV-TOPO>CONV-DTX>METRO-TOPO. Beta-actin was used as a control housekeeping gene (*, P ≤ 0.05). D, Assessment of treatment effect on “stem-like” cells (CD44high) population in taxane-resistant ARLow/mCRPC cell lines by FACS: DUTXR cell line stained with stemness markers (CD44) and sorted CD44+ versus CD44− cells, followed by CONV-TOPO, METRO-TOPO, CONV-DTX, and combination (CONV-DTX+METRO-TOPO) treatments. Next, cell cytotoxicity (MTT) and caspase 3/7 activity (apoptosis) were assessed. (I) Cytotoxicity profiling by MTT showed that combination (CONV-DTX+METRO-TOPO) treatment reduced highest cell survival or cell growth compared with other treatments. Posttreatment cell survival or cell growth reduction was following orders: CONV-TOPO>CONV-DTX>METRO-TOPO. (II) Combination (CONV-DTX+METRO-TOPO) treatment induced greater apoptosis compared with other treatments in taxane-resistant ARLow/mCRPC-DUTXR cell lines. (III and IV) CD44− cells showed no significant differences for all treatments (*, P ≤ 0.05). E, Pretreatment and posttreatment microscope imaging: Results showed significantly higher cell death in METRO-TOPO and combination (CONV-DTX+METRO-TOPO) treatments compared with CONV treatment for both the drugs (TOPO and DTX). Images were captured by Cytation5 Cell Imaging Multimode Reader at a 1,000 μm scale. ImageJ analysis showed a significant difference in cell density for CONV versus METRO versus combination TOPO treatments (*, P ≤ 0.05).
- 19 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 6 from Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers
Metronomic topotecan treatment as a single agent and in combination with DTX reduces EMT/stemness in ARLow/mCRPC/NEPC clonally derived taxane-resistant prostate cancer subtypes. A, Assessment of posttreated “stem-like” cells (CD44high/CD133high) population in taxane-resistant ARLow/mCRPC cell lines by Flow cytometry: DUTXR cells line stained with stemness markers (CD44, CD33, and both CD44/133) after CONV-TOPO, METRO-TOPO, and combination (CONV-DTX+METRO-TOPO) treatments. CONV-TOPO, METRO-TOPO, and combination (CONV-DTX+METRO-TOPO) treatments reduced CD44high cells 81.0%, 71.5%, and 63.4%, respectively, in taxane-resistant ARLow mCRPC DUTXR cells. Therefore, METRO-TOPO as single agent and in combination treatment reduced the highest percentage of “stem like” cell population load (P < 0.05; Table 2). B, Colony-forming assay: Number and size of colonies were reduced after all treatments compared with control (no-drug treatment). Next, combination treatment with CONV-DTX+METRO-TOPO reduced the number and size of colonies the greatest compared with CONV-TOPO, CONV-DTX, and METRO-TOPO treatments in the DUTXR cell line. Posttreatment colony number and size reduction in the following order: CONV-TOPO>CONV-DTX>METRO-TOPO>Combination (METRO-TOPO+CONV-DTX). Therefore, METRO-TOPO as a single agent or in combination reduced highest number of the colony and size compared with other treatments. Colonies were developed for 21 days (*, P ≤ 0.05). C, Immunoblot analysis: Proteins representing top EMT markers were downregulated significantly after METRO-TOPO treatment compared with CONV-TOPO treatment in ARLow/mCSPC/NEPCtaxane-resistant (DUTXR) prostate cancer cell lines. Combination treatment (CONV-DTX+METRO-TOPO) exhibited the highest downregulation of EMT marker proteins compared with other treatments. Posttreatment protein expression downregulation was following orders: CONV-TOPO>CONV-DTX>METRO-TOPO. Beta-actin was used as a control housekeeping gene (*, P ≤ 0.05). D, Assessment of treatment effect on “stem-like” cells (CD44high) population in taxane-resistant ARLow/mCRPC cell lines by FACS: DUTXR cell line stained with stemness markers (CD44) and sorted CD44+ versus CD44− cells, followed by CONV-TOPO, METRO-TOPO, CONV-DTX, and combination (CONV-DTX+METRO-TOPO) treatments. Next, cell cytotoxicity (MTT) and caspase 3/7 activity (apoptosis) were assessed. (I) Cytotoxicity profiling by MTT showed that combination (CONV-DTX+METRO-TOPO) treatment reduced highest cell survival or cell growth compared with other treatments. Posttreatment cell survival or cell growth reduction was following orders: CONV-TOPO>CONV-DTX>METRO-TOPO. (II) Combination (CONV-DTX+METRO-TOPO) treatment induced greater apoptosis compared with other treatments in taxane-resistant ARLow/mCRPC-DUTXR cell lines. (III and IV) CD44− cells showed no significant differences for all treatments (*, P ≤ 0.05). E, Pretreatment and posttreatment microscope imaging: Results showed significantly higher cell death in METRO-TOPO and combination (CONV-DTX+METRO-TOPO) treatments compared with CONV treatment for both the drugs (TOPO and DTX). Images were captured by Cytation5 Cell Imaging Multimode Reader at a 1,000 μm scale. ImageJ analysis showed a significant difference in cell density for CONV versus METRO versus combination TOPO treatments (*, P ≤ 0.05).
- Open Access
- 19 July 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 3 from Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers
Metronomic topotecan in combination with DTX showed potency against prostate cancer subtypes, ARLow/mCRPC/NEPC (PC-3, PC-3M, DU145) and ARLow/mCSPC/NEPCtaxane resistant (DUTXR) cells. Cytotoxicity: In vitro effect of metronomic and conventional administration of topotecan on prostate cancer cell lines was assessed. A, MTT assay: Cytotoxicity was measured following 72 hours of CONV-TOPO, CONV-DTX, METRO-TOPO, and the combination of CONV-DTX+METRO-TOPO treatment in PC-3, PC-3M, DU145, DUTXR cell lines using mitochondrial activity [3-(4, 5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] or the MTT assay. In all cell lines, METRO-TOPO (lower dose) reduced cell growth more compared with CONV (high dose) treatment at IC50/2. The greatest reduction in cell growth was observed following CONV-DTX + METRO-TOPO combination treatment in all prostate cancer cell lines tested (*, P ≤ 0.05). B, Apoptosis (caspase 3/7 assay): Levels of caspase 3/7 enzyme (a marker of apoptosis) activities measured followed CONV-TOPO, CONV-DTX, METRO-TOPO, and the combination of CONV-DTX + METRO-TOPO 72 hours treatment. Results showed significant increases in caspase 3/7 activity following each treatment compared with control. Results confirmed significantly greater treatment-induced apoptosis was observed for post-METRO-TOPO treatment compared with CONV-TOPO and DTX. The highest treatment-induced apoptosis was observed in combination with CONV-DTX+METRO-TOPO in all cell lines (*, P ≤ 0.05). C, Microscope images (Cytation5): Cell morphologic study reported micrographs of prostate cancer cells exposed to all dosing regimens showed decreases in cell density compared with control cells. Results showed that METRO-TOPO reduces higher cell density compared with CONV-TOPO and CONV-DTX. Highest cell death observed in CONV-DTX+METRO-TOPO combination treatment compared with CONV-TOPO, CONV-DTX, and METRO-TOPO single-drug treatment (*, P ≤ 0.05).
- 19 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 3 from Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers
Metronomic topotecan in combination with DTX showed potency against prostate cancer subtypes, ARLow/mCRPC/NEPC (PC-3, PC-3M, DU145) and ARLow/mCSPC/NEPCtaxane resistant (DUTXR) cells. Cytotoxicity: In vitro effect of metronomic and conventional administration of topotecan on prostate cancer cell lines was assessed. A, MTT assay: Cytotoxicity was measured following 72 hours of CONV-TOPO, CONV-DTX, METRO-TOPO, and the combination of CONV-DTX+METRO-TOPO treatment in PC-3, PC-3M, DU145, DUTXR cell lines using mitochondrial activity [3-(4, 5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] or the MTT assay. In all cell lines, METRO-TOPO (lower dose) reduced cell growth more compared with CONV (high dose) treatment at IC50/2. The greatest reduction in cell growth was observed following CONV-DTX + METRO-TOPO combination treatment in all prostate cancer cell lines tested (*, P ≤ 0.05). B, Apoptosis (caspase 3/7 assay): Levels of caspase 3/7 enzyme (a marker of apoptosis) activities measured followed CONV-TOPO, CONV-DTX, METRO-TOPO, and the combination of CONV-DTX + METRO-TOPO 72 hours treatment. Results showed significant increases in caspase 3/7 activity following each treatment compared with control. Results confirmed significantly greater treatment-induced apoptosis was observed for post-METRO-TOPO treatment compared with CONV-TOPO and DTX. The highest treatment-induced apoptosis was observed in combination with CONV-DTX+METRO-TOPO in all cell lines (*, P ≤ 0.05). C, Microscope images (Cytation5): Cell morphologic study reported micrographs of prostate cancer cells exposed to all dosing regimens showed decreases in cell density compared with control cells. Results showed that METRO-TOPO reduces higher cell density compared with CONV-TOPO and CONV-DTX. Highest cell death observed in CONV-DTX+METRO-TOPO combination treatment compared with CONV-TOPO, CONV-DTX, and METRO-TOPO single-drug treatment (*, P ≤ 0.05).
- Open Access
- 19 July 2023
- Published by American Association for Cancer Research (AACR)
TABLE 1 from Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers
Top DEGs for mCSPC/ARHigh (LNCaP, VCaP, 22RV1) and mCRPC/NEPC/ARLow (PC-3, PC3M, and DU145) prostate cancer cell lines
- 19 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 1 from Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers
Top DEGs for mCSPC/ARHigh (LNCaP, VCaP, 22RV1) and mCRPC/NEPC/ARLow (PC-3, PC3M, and DU145) prostate cancer cell lines
- Open Access
- 19 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers
Supplementary Fig. 5 shows Ingenuity pathway analysis (IPA) predictions for common DEGs among RNAseq vs. scRNAseq in all PCa cell lines IPA predicted A) Diseases and biological pathways for common DGEs. Major pathways are cell invasion, movement, neoplasia, migration, transformation, metastatic and growth B) Causal network pathway for common DEGS include LY2109761 (TGF-β receptor inhibitor), IGF2R (receptor for both insulin-like growth factor 2), IL11RA (cytokine), SEMG2 (semenogelin proteins), CCR2 (chemokine receptor type 2), TRAF3IP3 (mediates cell growth by modulating the c-Jun N-terminal kinase signal transduction pathway), GGTI-2154 (inhibitor of geranylgeranyltransferase I ), L778123 (inhibitor of FPTase and GGPTase-I), TGFB1 and CXCL5. C) upstream regulators for common DEGs were THBF1, RAF1, AGT, ER receptor, OSM, SLC15A4, JUN, and IL1B D) Canonical pathways for common DEGs were s100 family, Hepatic fibrosis, Rho family, RHOGDI and integrin singling pathway.
- 19 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers
Supplementary Fig. 5 shows Ingenuity pathway analysis (IPA) predictions for common DEGs among RNAseq vs. scRNAseq in all PCa cell lines IPA predicted A) Diseases and biological pathways for common DGEs. Major pathways are cell invasion, movement, neoplasia, migration, transformation, metastatic and growth B) Causal network pathway for common DEGS include LY2109761 (TGF-β receptor inhibitor), IGF2R (receptor for both insulin-like growth factor 2), IL11RA (cytokine), SEMG2 (semenogelin proteins), CCR2 (chemokine receptor type 2), TRAF3IP3 (mediates cell growth by modulating the c-Jun N-terminal kinase signal transduction pathway), GGTI-2154 (inhibitor of geranylgeranyltransferase I ), L778123 (inhibitor of FPTase and GGPTase-I), TGFB1 and CXCL5. C) upstream regulators for common DEGs were THBF1, RAF1, AGT, ER receptor, OSM, SLC15A4, JUN, and IL1B D) Canonical pathways for common DEGs were s100 family, Hepatic fibrosis, Rho family, RHOGDI and integrin singling pathway.
- Open Access
- 19 July 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 3 from Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers
Metronomic topotecan in combination with DTX showed potency against prostate cancer subtypes, ARLow/mCRPC/NEPC (PC-3, PC-3M, DU145) and ARLow/mCSPC/NEPCtaxane resistant (DUTXR) cells. Cytotoxicity: In vitro effect of metronomic and conventional administration of topotecan on prostate cancer cell lines was assessed. A, MTT assay: Cytotoxicity was measured following 72 hours of CONV-TOPO, CONV-DTX, METRO-TOPO, and the combination of CONV-DTX+METRO-TOPO treatment in PC-3, PC-3M, DU145, DUTXR cell lines using mitochondrial activity [3-(4, 5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] or the MTT assay. In all cell lines, METRO-TOPO (lower dose) reduced cell growth more compared with CONV (high dose) treatment at IC50/2. The greatest reduction in cell growth was observed following CONV-DTX + METRO-TOPO combination treatment in all prostate cancer cell lines tested (*, P ≤ 0.05). B, Apoptosis (caspase 3/7 assay): Levels of caspase 3/7 enzyme (a marker of apoptosis) activities measured followed CONV-TOPO, CONV-DTX, METRO-TOPO, and the combination of CONV-DTX + METRO-TOPO 72 hours treatment. Results showed significant increases in caspase 3/7 activity following each treatment compared with control. Results confirmed significantly greater treatment-induced apoptosis was observed for post-METRO-TOPO treatment compared with CONV-TOPO and DTX. The highest treatment-induced apoptosis was observed in combination with CONV-DTX+METRO-TOPO in all cell lines (*, P ≤ 0.05). C, Microscope images (Cytation5): Cell morphologic study reported micrographs of prostate cancer cells exposed to all dosing regimens showed decreases in cell density compared with control cells. Results showed that METRO-TOPO reduces higher cell density compared with CONV-TOPO and CONV-DTX. Highest cell death observed in CONV-DTX+METRO-TOPO combination treatment compared with CONV-TOPO, CONV-DTX, and METRO-TOPO single-drug treatment (*, P ≤ 0.05).
- 19 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 3 from Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers
Metronomic topotecan in combination with DTX showed potency against prostate cancer subtypes, ARLow/mCRPC/NEPC (PC-3, PC-3M, DU145) and ARLow/mCSPC/NEPCtaxane resistant (DUTXR) cells. Cytotoxicity: In vitro effect of metronomic and conventional administration of topotecan on prostate cancer cell lines was assessed. A, MTT assay: Cytotoxicity was measured following 72 hours of CONV-TOPO, CONV-DTX, METRO-TOPO, and the combination of CONV-DTX+METRO-TOPO treatment in PC-3, PC-3M, DU145, DUTXR cell lines using mitochondrial activity [3-(4, 5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] or the MTT assay. In all cell lines, METRO-TOPO (lower dose) reduced cell growth more compared with CONV (high dose) treatment at IC50/2. The greatest reduction in cell growth was observed following CONV-DTX + METRO-TOPO combination treatment in all prostate cancer cell lines tested (*, P ≤ 0.05). B, Apoptosis (caspase 3/7 assay): Levels of caspase 3/7 enzyme (a marker of apoptosis) activities measured followed CONV-TOPO, CONV-DTX, METRO-TOPO, and the combination of CONV-DTX + METRO-TOPO 72 hours treatment. Results showed significant increases in caspase 3/7 activity following each treatment compared with control. Results confirmed significantly greater treatment-induced apoptosis was observed for post-METRO-TOPO treatment compared with CONV-TOPO and DTX. The highest treatment-induced apoptosis was observed in combination with CONV-DTX+METRO-TOPO in all cell lines (*, P ≤ 0.05). C, Microscope images (Cytation5): Cell morphologic study reported micrographs of prostate cancer cells exposed to all dosing regimens showed decreases in cell density compared with control cells. Results showed that METRO-TOPO reduces higher cell density compared with CONV-TOPO and CONV-DTX. Highest cell death observed in CONV-DTX+METRO-TOPO combination treatment compared with CONV-TOPO, CONV-DTX, and METRO-TOPO single-drug treatment (*, P ≤ 0.05).
- Open Access
- 19 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers
Supplementary Fig. 6 shows Cytotoxicity Profiling of ARLow/mCRPC/NEPC (PC-3 and PC-3M) and Taxane Resistance ARLow/mCRPC (DUTXR): PC-3, PC-3M and DUTXR cell lines were treated with CONV-TOPO, METRO-TOPO, CONV-DTX and combination (CONV-DTX+METRO-TOPO) treatment, and cell cytotoxicity and caspase3/7 levels ware assed A) Cytotoxicity profiling by MTT showed combination (CONV-DTX+METRO-TOPO) reduces highest cell survival compared with other treatments for all PCa cell lines, CONV-TOPO>CONV-DTX>METRO-TOPO B) Caspase3/7 activity showed combination (CONV-DTX+METRO-TOPO) treatment reduced apoptosis the greatest compared to other treatments in all cell lines. C) Cytation5 images showed treatment effects on the cell lines PC-3M and DUTXR. Results showed significantly higher cell death in METRO compared to CONV treatment for both the cell lines and combination (CONV-DTX+METRO-TOPO) treatment reduced cell death greater for both PCa cell lines. ImageJ analysis showed significant differences in cell density for CONV-TOPO, CONV-DTX, METRO-TOPO, and combination (CONV-DTX+METRO-TOPO) treatment in PC-3, PC-3M, and DUTXR cell lines. (*p ≤ 0.05).
- 19 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers
Supplementary Fig. 6 shows Cytotoxicity Profiling of ARLow/mCRPC/NEPC (PC-3 and PC-3M) and Taxane Resistance ARLow/mCRPC (DUTXR): PC-3, PC-3M and DUTXR cell lines were treated with CONV-TOPO, METRO-TOPO, CONV-DTX and combination (CONV-DTX+METRO-TOPO) treatment, and cell cytotoxicity and caspase3/7 levels ware assed A) Cytotoxicity profiling by MTT showed combination (CONV-DTX+METRO-TOPO) reduces highest cell survival compared with other treatments for all PCa cell lines, CONV-TOPO>CONV-DTX>METRO-TOPO B) Caspase3/7 activity showed combination (CONV-DTX+METRO-TOPO) treatment reduced apoptosis the greatest compared to other treatments in all cell lines. C) Cytation5 images showed treatment effects on the cell lines PC-3M and DUTXR. Results showed significantly higher cell death in METRO compared to CONV treatment for both the cell lines and combination (CONV-DTX+METRO-TOPO) treatment reduced cell death greater for both PCa cell lines. ImageJ analysis showed significant differences in cell density for CONV-TOPO, CONV-DTX, METRO-TOPO, and combination (CONV-DTX+METRO-TOPO) treatment in PC-3, PC-3M, and DUTXR cell lines. (*p ≤ 0.05).
- Open Access
- 19 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers
Supplementary Fig. 8 shows Flow Cytometry; Prostate cancer cell lines stained with stemness markers (CD44, CD133 and CD44/133) to determine the percent of CD44+, CD133+ and double positive cells among PCa subtypes. Treatments with CONV-TOPO, METRO-TOPO and CONV-DTX+METRO-TOPO reduced stemness. METRO-TOPO reduced CD44+ cells to a greater extent compared to CONV-TOPO and CONV-DTX treatments, whereas combination treatment with CONV-DTX+METRO-TOPO reduced stemness (CD44+ cells) the most in ARHigh/mCRPC/NEPC. A) PC-3M, B) DU145 cell lines.
- 19 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers
Supplementary Fig. 8 shows Flow Cytometry; Prostate cancer cell lines stained with stemness markers (CD44, CD133 and CD44/133) to determine the percent of CD44+, CD133+ and double positive cells among PCa subtypes. Treatments with CONV-TOPO, METRO-TOPO and CONV-DTX+METRO-TOPO reduced stemness. METRO-TOPO reduced CD44+ cells to a greater extent compared to CONV-TOPO and CONV-DTX treatments, whereas combination treatment with CONV-DTX+METRO-TOPO reduced stemness (CD44+ cells) the most in ARHigh/mCRPC/NEPC. A) PC-3M, B) DU145 cell lines.
- Open Access
- 19 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Video 4 from Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers
Supplementary Video 4 from Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers
- 19 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video 4 from Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers
Supplementary Video 4 from Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers
- Open Access
- 19 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Video 1 from Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers
Supplementary Video 1 from Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers
- 19 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video 1 from Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers
Supplementary Video 1 from Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers